Meeting
2016 ASCO Annual Meeting
A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer.
Authors
Gottfried E. Konecny
UCLA, Santa Monica, CA
Gottfried E. Konecny , Andrea Elisabeth Wahner Hendrickson , Aminah Jatoi , Jill K. Burton , Jill Paroly , John A. Glaspy , Sean Christopher Dowdy , Dennis J. Slamon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01536743
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5557)
DOI
10.1200/JCO.2016.34.15_suppl.5557
Abstract #
5557
Poster Bd #
380
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase II trial of palbociclib in recurrent RB-positive anaplastic oligodendroglioma: A Spanish group for research in neurooncology (GEINO) trial.
First Author: Juan Manuel Sepulveda-Sanchez
Poster
2016 ASCO Annual Meeting
An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 study of palbociclib (an oral CDK4/6 inhibitor) plus cetuximab in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
First Author: Bhumsuk Keam
Poster
2023 ASCO Annual Meeting
Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial.
First Author: Peter John Oppelt
Poster
2023 ASCO Annual Meeting
Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).
First Author: Alicia Frances Clare Okines